ImmunityBio (IBRX) Current Assets (2014 - 2026)

ImmunityBio (IBRX) has 13 years of Current Assets data on file, last reported at $453.0 million in Q1 2026.

• On a quarterly basis, Current Assets rose 314.93% year-over-year to $453.0 million in Q1 2026; TTM through Mar 2026 was $453.0 million, a 314.93% increase from a year earlier, with the FY2025 full-year figure at $314.9 million, up 70.58% from the prior year.
• Current Assets for Q1 2026 stood at $453.0 million, up from $314.9 million in the prior quarter.
• Over the last five years, Current Assets for IBRX reached as high as $453.0 million in Q1 2026 and fell as low as $66.8 million in Q2 2023.
• Historically, Current Assets has averaged $206.0 million across 5 years, with a median of $195.7 million in 2024.
• Across the five-year window, Current Assets plunged 57.95% in 2022 and surged 314.93% in 2026, its largest moves.
• Year by year, Current Assets stood at $140.6 million in 2022, then soared by 109.2% to $294.1 million in 2023, then plunged by 37.23% to $184.6 million in 2024, then soared by 70.58% to $314.9 million in 2025, then soared by 43.85% to $453.0 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $453.0 million in Q1 2026, $314.9 million in Q4 2025, and $329.5 million in Q3 2025.